Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2013.594 | A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate with Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects with Overactive Bladder | Dr. CHAN Symphorosa Shing Chee |
| 2013.477 | A follow up study on pelvic floor disorders related to post-instrumental deliveries | Dr. CHAN Symphorosa Shing Chee |
| 2015.203 | A pilot study to explore the diagnoses of urinary incontinence in women according to Traditional Chinese Medicine |
Dr. CHAN Symphorosa Shing chee 陳丞智 |
| 2015.125 | PROSPECTIVE OBSERVATIONAL STUDY OF OUTCOME OF TREATMENT TO WOMEN WITH PELVIC FLOOR DISORDERS |
Dr. CHAN Symphorosa Shing Chee 陳丞智 |
| 2015.510 | Acupuncture for urinary incontinence in Chinese women: a randomized controlled trial |
Dr. CHAN Symphorosa Shing Chee 陳丞智 |
| 2017.005 | The prevalence of obstetric anal sphincter injury following vaginal delivery in Chinese primiparous women |
Dr. CHAN Symphorosa Shing Chee 陳丞智 |
| 2015.085 | Symptom and Quality of life measurements in Chinese women with uterine fibroid – Validation study of The Uterine Fibroid Symptom and Quality of Life questionnaire |
Dr. CHAN Symphorosa Shing Chee 陳丞智 |
| 2016.081 | A randomised controlled trial on routine episiotomy versus restrictive episiotomy in Chinese nulliparous women |
Dr. CHAN Symphorosa Shing Chee 陳丞智 |
| 2018.387 | A randomized controlled trial of laser treatment in women with stress urinary incontinence |
Dr. CHAN Symphorosa Shing Chee 陳丞智 |
| 2009.257 | A propective observational study on pelvic floor disorders related to pregnancy | Dr Chan Symphorosa Shing Chee |
| 2013.332 | An observational follow up study on pelvic floor disorders related to 3 years after delivery | Dr. CHAN Symphorosa Shing Chee |
| 2022.617 | Effect of Virtual Reality and Music Therapy on Pain Relief in Outpatient Hysteroscopic Operations: A Randomized Controlled Trial |
Dr. CHAN Symphorosa Shing Chee 陳丞智 |
| 2023.603 | The attitude and success rate of women with pelvic organ prolapse on self-management of vaginal pessary: a multi-centered prospective study |
Dr. CHAN Symphorosa Shing Chee Shing Chee Symphorosa CHAN |
| 2024.176 | A Randomized Controlled Trial of High-Intensity Focused Ultrasound (HIFU) Versus Myomectomy for the Treatment of Symptomatic Uterine Fibroids | Dr. CHAN Symphorosa Shing Chee |
| 2013.379 | A pilot cross-sectional study examining the dietary intakes, nutrient intakes and nutritional status of Chinese women from early pregnancy to early postpartum in Hong Kong | Prof Chan Suk-mei, Ruth |
| 2012.530 | A randomized crossover trial to compare the changes of postprandial oxidative stress after consumption of meals from different cultures in healthy Chinese adults | Prof Chan Suk-mei Ruth |
| 2024.062 | Increased Incidence of Paediatric Graves' Disease in Hong Kong Before and During COVID-19 | Dr Chan Suk Yan Suki |
| 2017.477 | Frailty Intervention Trial for Healthy Ageing (FIT for Age): A randomized controlled trial assessing the effect of exercise program and individualized dietary recommendation on frailty | Prof. CHAN Suk Mei |
| 2013.258 | Self-Control Interventions for Children with Autism Spectrum Disorders: Computerized Training vs Chinese Mind-Body Exercise | Prof. Chan Sui-yin, Agnes |
| 2008.127 | Experimental Study on the Psychophysiological and Neuropsychological Effects of Mindfulness-based Dan Tian Breathing Exercises in a Community Sample of Healthy and Depressed Individuals | Professor Chan Sui-yin |
| 2023.133 | A prospective evaluation of early return-to-work (RTW) intervention group for patients with lower limbs injury in work rehabilitation program |
Ms. CHAN Sui Mei 陳瑞薇 |
| 2013.557 | A telephone follow-up study on work-related factors of return-to-work (RTW) among injured workers after musculoskeletal injury for 2 years | Ms Chan Sui Mei |
| 2011.370 | Noninvasive cardiac output monitoring to optimise therapy for patients with poorly controlled hypertension: a randomised controlled trial | Dr. Chan Stewart |
| 2011.094 | Current medical practice and relationships between medical treatment and cardiovascular indices measured by USCOM (Ultrasonic Cardiac Output Monotor) in patients with poorly controlled hypertension | Dr. Chan Stewart |
| 2011.388 | Prevalence of poorly controlled hypertension in Emergency Department patients in Hong Kong and the characteristics, disposition, referral or follow up patterns of these patients | Dr. Chan Stewart |
| 2021.154 | A Phase 2, Randomized, Open-label Study of Relatlimab in Combination with Nivolumab in Participants with Advanced Hepatocellular Carcinoma who are Naive to IO Therapy but Progressed on Tyrosine Kinase Inhibitors (RELATIVITY-073) |
Dr. CHAN Stephen Lam 陳林 |
| 2022.533 | Artificial Intelligence for the Immune Profiling of Hepatocellular Carcinoma (AI-Immune-HCC) |
Prof. CHAN Stephen Lam 陳林教授 |
| 2021.638 | A Multicountry, Multicentre, Noninterventional, Retrospective Study to Describe the Real-world Management Outcomes in Patients With Unresectable Hepatocellular Carcinoma |
Prof. CHAN Stephen Lam 陳林 |
| 2021.605 | ORGAN-SPECIFIC RESPONSES TO ATEZOLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: A MULTINATIONAL MULTICENTER STUDY |
Prof. CHAN Stephen Lam 陳林教授 |
| 2022.174 | AN OPEN LABEL, RANDOMISED, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MTL-CEBPA ADMINISTERED IN COMBINATION WITH SORAFENIB OR SORAFENIB ALONE, IN TKI NAÏVE PARTICIPANTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA (HCC) AND HEPATITIS B OR HEPATITIS C VIRUS (OUTREACH2) |
Prof. CHAN Stephen Lam 陳林 |
| 2022.175 | Sequential TransArterial chemoembolization and stereotactic RadioTherapy Followed by Durvalumab (MEDI4736) and Tremelimumab for downstaging hepatocellular carcinoma for hepatectomy |
Prof. CHAN Stephen Lam 陳林醫生 |
| 2022.007 | Epigenetic therapeutics to overcome resistance against immune checkpoint inhibitors in hepatocellular carcinoma: A proof-of-concept clinical trial |
Prof. CHAN Stephen Lam 陳林 |
| 2023.423 | A Clinical Study of Consistency Evaluation on Patient-Derived Organoid in Predicting Treatment Response for Hepatobiliary and Pancreatic Cancer | Prof. CHAN Stephen Lam |
| 2024.003 | A retrospective study on the outcome of patients with pancreatic neuroendocrine tumour in a regional setting | Prof. CHAN Stephen Lam |
| 2022.216 | A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination with Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma (RELATIVITY-106) |
Prof. CHAN Stephen Lam 陳林 |
| 2023.513 | A phase III, multicenter, randomized, open-label trial to evaluate the safety and efficacy of systemic therapy with regorafenib and pembrolizumab versus locoregional therapy with transarterial chemoembolization (TACE) or transarterial radioembolization (TARE), for the first-line treatment of intermediate-stage hepatocellular carcinoma with beyond up-to-7 criteria (REPLACE) | Prof. CHAN Stephen Lam |
| 2023.376 | A Phase II, Open-Label, Multi-Drug, Multi-Centre, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary) Sub-study 2: Biliary Tract Cancer (BTC) | Prof. CHAN Stephen Lam |
| 2023.345 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING ATEZOLIZUMAB AND BEVACIZUMAB, WITH OR WITHOUT TIRAGOLUMAB, IN PATIENTS WITH UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA |
Prof. CHAN Stephen Lam 陳林 |
| 2021.428 | Survival analysis for prognostic factors in biliary tract cancer |
Dr. CHAN Stephen Lam 陳林醫生 |
| 2021.629 | RETROSPECTIVE NON-INTERVENTIONAL STUDY OF THE EFFECTIVENESS AND SAFETY OF LANREOTIDE AUTOGEL® AT A DOSE OF 120 MG ONCE EVERY 28 DAYS IN ROUTINE CLINICAL PRACTICE IN PATIENTS WITH GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOURS (GEP-NETS) IN HONG KONG AND TAIWAN |
Prof. CHAN Stephen Lam 陳林教授 |
| 2022.403 | A Phase 1/ 2a, multicenter study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma |
Prof. CHAN Stephen Lam 陳林 |
| 2023.567 | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01) | Prof. CHAN Stephen Lam |
| 2024.098 | Establishment of a Hepatocellular Carcinoma Database | Prof. CHAN Stephen Lam |
| 2023.103 | A Phase II, Open-Label, Multi-Drug, Multi-Centre, Master Protocol to Evaluate the Efficacy and Safety of Novel Immunomodulators as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hepatobiliary Cancer (GEMINI-Hepatobiliary) Sub-study 1: Hepatocellular Carcinoma (HCC) | Prof. CHAN Stephen Lam |
| 2023.104 | A Phase IIIb Single Arm, Open-label, Multicentre Study of Durvalumab and Tremelimumab as First Line Treatment in Participants with Advanced Hepatocellular Carcinoma (SIERRA) | Prof. CHAN Stephen Lam |
| 2021.017 | A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination with Trans-arterial ChemoEmbolization (TACE) in Patients with Intermediate-stage Hepatocellular Carcinoma (HCC) |
Dr. CHAN Stephen Lam 陳林 |
| 2022.463 | A Phase 1/2 open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of OTX-2002 as a single agent and in combination with standard of care in patients with hepatocellular carcinoma and other solid tumor types known for association with the MYC oncogene |
Prof. CHAN Stephen Lam 陳林 |
| 2021.642 | A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) with Pembrolizumab (MK-3475) in Combination with Transarterial Chemoembolization (TACE) Versus TACE in Participants with Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012) |
Prof. CHAN Stephen Lam 陳林教授 |
| 2010.603 | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Trial of AMG 479 or Placebo in Combination with Gemcitabine as First-line Therapy for Metastatic Adenocarcinoma of the Pancreas | Dr Chan Stephen Lam |
| 2011.030 | A multicenter, global, randomized, double-blind study of axitinib plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma following failure of one prior antiangiogenic therapy | Prof. CHAN Stephen Lam |
Page 195 of 262.